Related Experiment Video
Updated: May 30, 2025

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells
Published on: March 14, 2021
Model construction and clinical therapeutic potential of engineered cardiac organoids for cardiovascular diseases
Yongtao Wang1,2, Yan Hou1, Tian Hao3
1Cardiac Regeneration and Ageing Lab, School of Medicine, Shanghai University, Shanghai, China.
Abstract:
Cardiovascular diseases cause significant morbidity and mortality worldwide. Engineered cardiac organoids are being developed and used to replicate cardiac tissues supporting cardiac morphogenesis and development. These organoids have applications in drug screening, cardiac disease models and regenerative medicine. Therefore, a thorough understanding of cardiac organoids and a comprehensive overview of their development are essential for cardiac tissue engineering. This review summarises different types of cardiac organoids used to explore cardiac function, including those based on co-culture, aggregation, scaffolds, and geometries. The self-assembly of monolayers, multilayers and aggravated cardiomyocytes forms biofunctional cell aggregates in cardiac organoids, elucidating the formation mechanism of scaffold-free cardiac organoids. In contrast, scaffolds such as decellularised extracellular matrices, three-dimensional hydrogels and bioprinting techniques provide a supportive framework for cardiac organoids, playing a crucial role in cardiac development. Different geometries are engineered to create cardiac organoids, facilitating the investigation of intrinsic communication between cardiac organoids and biomechanical pathways. Additionally, this review emphasises the relationship between cardiac organoids and the cardiac system, and evaluates their clinical applications. This review aims to provide valuable insights into the study of three-dimensional cardiac organoids and their clinical potential.

